Free tool
FAERS Monitor: Biktarvy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210251 or its brand name (Biktarvy, Bictegravir Sodium, Emtricitabine, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.
Reports
18,385
Serious
13,377
73% of reports
Hospitalization
2,244
Death reported
732
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bone density decreased6,649
- chronic kidney disease3,668
- bone loss3,491
- tooth loss3,445
- osteonecrosis3,405
- multiple fractures3,153
- renal failure3,059
- osteoporosis2,794
- pain2,549
- renal injury2,489
- emotional distress2,436
- anxiety2,283
- anhedonia2,154
- skeletal injury2,123
- osteopenia1,884
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 1 |
| 2018 | 363 |
| 2019 | 1,482 |
| 2020 | 5,609 |
| 2021 | 2,570 |
| 2022 | 2,257 |
| 2023 | 1,630 |
| 2024 | 1,854 |
| 2025 | 1,709 |
| 2026 | 901 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,774 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone lossSignal | 3,491 | 345.6 | 333.7 | 921,689 |
| bone density decreasedSignal | 6,649 | 307.8 | 300.8 | 1,604,418 |
| skeletal injurySignal | 2,123 | 295.2 | 282.1 | 494,802 |
| multiple fracturesSignal | 3,153 | 271.4 | 261.8 | 686,958 |
| tooth lossSignal | 3,445 | 227.7 | 220.2 | 648,977 |
| osteopeniaSignal | 1,884 | 162.0 | 154.7 | 264,120 |
| osteonecrosisSignal | 3,405 | 132.2 | 128.0 | 397,891 |
| renal injurySignal | 2,489 | 104.5 | 100.6 | 234,024 |
| anhedoniaSignal | 2,154 | 102.0 | 97.9 | 198,016 |
| osteoporosisSignal | 2,794 | 83.3 | 80.4 | 212,104 |
| chronic kidney diseaseSignal | 3,668 | 58.0 | 56.3 | 196,131 |
| renal failureSignal | 3,059 | 27.0 | 26.1 | 75,126 |
| emotional distressSignal | 2,436 | 23.5 | 22.6 | 51,629 |
| anxietySignal | 2,283 | 9.2 | 8.9 | 16,869 |
| painSignal | 2,549 | 4.8 | 4.6 | 7,769 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.